Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.48 |
| ▸ | MTOR | P42345 | 8/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442229 | 0.83 | PIK3CA (0.53) | MEN1KMT2AALDH1A1MAPK1PIK3CA | |
| SCHEMBL4443377 | 0.82 | PIK3CA (0.70) | PIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL4440268 | 0.82 | PIK3CA (0.62) | MEN1KMT2ASRCPIK3CAMTOR | |
| SCHEMBL4449352 | 0.81 | KDM4E (0.54) | MAPK1PIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL4437743 | 0.80 | PIK3CA (0.72) | PIK3CAMTORPIK3CGPIK3CDLMNA | |
| SCHEMBL4442257 | 0.80 | PIK3CA (0.71) | PIK3CAMTORPIK3CGPIK3CDLMNA | |
| SCHEMBL4442920 | 0.80 | PIK3CA (0.50) | PIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL4443717 | 0.80 | PIK3CA (0.58) | MEN1KMT2AALDH1A1MAPK1SRC | |
| SCHEMBL4449028 | 0.80 | GAA (0.59) | PIK3CAMTORPIK3CGPIK3CD | |
| SCHEMBL4438221 | 0.78 | PIK3CA (0.75) | MEN1KMT2AMAPK1PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125815-A2 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008116129-A2 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080233127-A1 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | claimed |
| US-20080233127-A1 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080233127-A1 | IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, MTMR1 | MEN1 2870/4885KMT2A 2923/4885ALDH1A1 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.